Nucleo CMP Forte capsules

국가: 아르메니아

언어: 영어

출처: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Download 제품 특성 요약 (SPC)
21-04-2023

유효 성분:

cytidine-5-disodium monophosphate + (uridine-5-trisodium triphosphate, uridine-5-disodium diphosphate, uridine-5-disodium monophosphate)

제공처:

Ferrer International

ATC 코드:

առկա չէ (M09AX)

INN (국제 이름):

cytidine-5-disodium monophosphate + (uridine-5-trisodium triphosphate, uridine-5-disodium diphosphate, uridine-5-disodium monophosphate)

복용량:

5mg+ 3mg

약제 형태:

capsules

패키지 단위:

(30/2x15/) in blister

처방전 유형:

OTC

승인 상태:

Registered

승인 날짜:

2023-04-21

제품 특성 요약

                                NUCLEO CMP FORTE CAPSULES
SUMMARY PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT:
NUCLEO CMP FORTE capsules
2. QUALITATIVE AND QUANTITATIVE COMPOSITION.
Composition:
Per capsule:
Cytidine-5’-disodium monophosphate (CMP disodium salt)… 5 mg
Uridine-5’-trisodium triphosphate (UTP trisodium salt)
Uridine-5’-disodium diphosphate (UDP disodium salt)
Uridine-5’-disodium monophosphate (UMP disodium salt)
on the whole ………………………………… 3 mg
(equivalent to 1.330 mg of Uridine )
3. PHARMACEUTICAL FORM:
-
30
capsules
with
blue-coloured
head
and
grey
body
containing
a
white
and
hygroscopic powder.
4. CLINICAL PARTICULARS:
4.1. THERAPEUTICAL INDICATIONS:
Treatment
of
neuropathies
of
osteoarticular
(sciatica,
radiculitis,
etc.),
metabolic
(diabetic, alcoholic polyneuritis, etc.), infectious (herpes zoster)
origin, and a frigore.
Neuralgia of the Facial, Trigeminal, Intercostal, Lumbago.
4.2. POSOLOGY AND METHOD OF ADMINISTRATION:
- Nucleo CMP Forte capsules is administered by oral route.
Dosage:
Adults: 1 or 2 capsules 2 times daily.
Children: 1 capsule 2 times daily. As prescribed by physician.
4.3. CONTRAINDICATIONS:
Not known. Unless that there exists an allergy to any of the
components.
4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE:
Not applicable
4.5. INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION:
Not known.
4.6. PREGNANCY AND LACTATION:
Its use during pregnancy is not contraindicated. However, it is
recommended that the
dosage pattern is established by the physician.
4.7. EFFECTS ON THE ABILITY TO DRIVE AND USE MACHINES
Not applicable
4.8. UNDESIRABLE EFFECTS:
Have not been described, but if any adverse reaction attributable to
the taking of the
medicament appears, consult your physician or pharmacist.
4.9. OVERDOSE:
Given the scarce toxicity of the preparation, poisoning is not
foreseen, even by accident.
5. PHARMACOLOGICAL PROPERTIES
5.1. PHARMACODYNAMIC PROPERTIES:
ATC CODE N07XX (OTHER NERVOUS SYSTEM DRUGS)
NUCLEO CMP FORTE is an association of nuc
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 러시아어 21-04-2023